Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Dee Capital, with additional investments from West Lake Photonics, HWealth Capital, Topology Capital, Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd, and Ke Xi Capital.
Advancements in Artificial Kidney and Pancreas Products
Founded in 2018, Asia Regenerative Medicine possesses a GMP-aligned biological artificial organ equipment and cell workshop. The company is preparing to file Investigational New Drug (IND) applications for its artificial kidney and pancreatic products next year. The recent funding is anticipated to accelerate the commercialization of these innovative products.- Flcube.com
